PAS
CLDX icon

Point72 Asia (Singapore)’s Celldex Therapeutics CLDX Stock Holding History

Point72 Asia (Singapore)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-566
Closed -$11.5K – 952
2025
Q2 		$11.5K Sell
566
-1,232
-69% -$24K ﹤0.01% 787
2025
Q1 		$32.6K Buy
+1,798
New +$40.2K 0.01% 632
2024
Q4 		– Sell
-1,210
Closed -$41.1K – 918
2024
Q3 		$41.1K Sell
1,210
-843
-41% -$32.1K 0.01% 724
2024
Q2 		$76K Buy
+2,053
New +$77.5K 0.02% 550

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asia (Singapore)'s CLDX Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 566 shares — an estimated $11.5K sold.

Point72 Asia (Singapore) first reported a position in CLDX in Q2 2024 and held it in 4 quarters. The position peaked at $76K in Q2 2024. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 566 Celldex Therapeutics shares in Q3 2025, an estimated $11.5K.
  • Point72 Asia (Singapore) first reported a position in Celldex Therapeutics in Q2 2024 and held it in 4 quarters.
  • Point72 Asia (Singapore)'s Celldex Therapeutics position peaked at $76K in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.